Bitter Pill for David Healy: academia under pharma influence

Bitter Pill for David Healy: academia under pharma influence May 21, 2002 One wonders how many embarrassing causes celebres are needed before academic institutions take back control of the university from the corrosive influence of the pharmaceutical/ biotech industry? In 2000, Dr. David Healy may have been surprised by the…

Harvard research in China: Open Letter to Pres. Summers

Harvard research in China: Open Letter to Pres. Summers Sat, 12 Apr 2003 On May 15, 2002, The Boston Globe reported that Lawrence Summers, the President of Harvard University, “expressed deep regret that a dozen Harvard-run genetic studies in China failed to give test subjects adequate information about potential pitfalls.”…

Dissenting Opinion – Proposed Children’s Workgroup Reinterpretation of Fed Regs 45 CFR 46 sects. 404 & 406

Dissenting Opinion (NHRPAC Children Workgroup) re: Proposed Reinterpretation of Fed. Regs Protecting Children (45 CFR 46, sections 404 and 406) May 14, 2002 To: Alan Fleischman, MD, Chair, Children’s Workgroup of NARPAC        Mary Faith Marshall, Ph.D., Chair, NARPAC From: Vera Hassner Sharav Re: Dissenting Opinion re: Report to NHRPAC, proposing…

InfoMail for May 13, 2002

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav May 13, 2002 Experimentationon Newborns: Is it Ethical? FYI The Wall Street Journal reported: "Oneoutrage now before a court has stunned even bioethicists who thought they’d seenit…

Conflicts of Interest in Clinical Trials

Presented by Vera Hassner Sharav
14th Tri-Service Clinical Investigation Symposium
Sponsored by The U.S. Army Medical Department and The Henry M. Jackson Foundation for the Advancment of Military Medicine

The cornerstone of public trust in medical research is the integrity of academic institutions and the expectation that universities, which rely on public funding, have a responsibility to serve the public good. Financial conflicts of interest affect millions of American people – those who are subjects of clinical trials testing new drugs and those who are prescribed drugs after their approval.

Sharav Presentation before US Army Medical Dept., May 6, 2002

CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S. ARMY MEDICAL DEPARTMENT And THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCMENT OF MILITARY MEDICINE May 5-7, 2002 The cornerstone of public trust in medical research is the integrity of academic institutions and…

InfoMail for April 29, 2002

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 29, 2002 China Daily: Harvard Project ViolatesFarmers’ Rights FYI American experiments on impoverished populations inunderdeveloped countries needs much more oversight than seems to have beenprovided. XIONG…

Protecting Human Subjects in Research: Are Current Safeguards Adequate?

Current federal regulations set no limits on the level of risk that a competent adult may voluntarily choose to undertake for the sake of science. The regulations require prior approval by a review board (IRB) to ensure the research meets scientific and ethical justification, to ensure that the risks and benefits (if any) are fully disclosed to the subject, and that the subject can exercise the right to give or withhold informed consent.

InfoMail for April 22, 2002

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 22, 2002 ScientificMisconduct Notices FYI Scientific misconduct is a big problem undermining theintegrity of the scientific literature. Data falsification leads others toerroneous conclusions that may have…

Abortion Pill Tested in clinical Trials for Severe Depression – NYT

Abortion Pill Tested in clinical Trials for Severe Depression_NYT Mon, 28 Oct 2002 The New York Times reported that Corcept Therapeutics is testing the controversial abortion pill, Mifepristone (formerly known as RU-486, brand name, Mifreprex), in clinical trials for the treatment of severe depression. The article uncritically transcribed the sponsors’…

InfoMail for April 19, 2002

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 19, 2002 DHHS / FDA flip-flopsecond time re: " pediatric rule" FYI Tommy Thompson, Secretary of The Department of Health andHuman Services has reversed the FDA’s…

InfoMail for April 17, 2002

  AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 17, 2002 Scandal: Scientists Take Cash forGhostwritten Papers FYI The pharmaceutical industry has gained unprecedentedcontrol over research data. The published papers ended up being written byghostwriters–company…